GENETIC EPIDEMIOLOGY AND RISK ASSESSMENT PROGRAM PROJECT SUMMARY The unifying goal of the Genetic Epidemiology and Risk Assessment (GERA) Program is the application of genetic and molecular epidemiology methods to the study of critical questions addressing the etiology, prognosis, and survivorship of cancer in human populations. More specifically, GERA members leverage the combination of epidemiologic methods with high-resolution molecular techniques in order to identify risk and prognostic factors; improve risk stratification; and provide an evidence base for primary, secondary, and tertiary prevention strategies. This goal is further accelerated by applying novel and innovative methods from statistics and informatics. To address these fundamental questions, 3 scientific aims have been developed: 1) To use the tremendous advances in genetics and molecular biology to understand genetic, environmental, and gene?environment interactions in the etiology of cancer in human populations; 2) To use these same advances to understand the molecular epidemiology of cancer prognosis and survivorship; and 3) To develop and apply novel statistical and informatics methods for the design and analysis of genetic and molecular epidemiology studies. The GERA Program's cancer etiology studies use family-based, case-control, and cohort study designs and focus on the genetic epidemiology of cancer, premalignant conditions, and intermediate phenotypes, as well as nongenetic risk factors and descriptive epidemiology. Etiologic heterogeneity based on tumor phenotype is also being addressed. Cancer prognosis research focuses on host factors, including genetic and serum biomarkers as well as lifestyle factors that influence prognosis; tumor biomarkers; and survivorship. Novel methods for the design and analysis of genetic and molecular epidemiologic studies are being developed, building on our expertise in biostatistics, medical informatics, and bioinformatics. To achieve these goals we have assembled a team of 29 multidisciplinary members from 4 departments from all 3 campuses. Total direct peer-reviewed funding is $3.6M (79% from the NCI), with total direct funding of $5.4M. Since 2013, the program has generated 744 publications, 36% reflecting intraprogrammatic collaborations and 59% reflecting interprogrammatic collaborations. Notable contributions have been made in the epidemiology of pancreatic, lung, ovarian, breast, colon, prostate, and lymphoproliferative malignancies as well as to the statistical genetics and medical and bioinformatics literature. Leadership of the program is provided by Drs. Cerhan, Parker, and Yang. The Program makes extensive use of Shared Resources. In the next 5 years, we will facilitate innovative research in cancer etiology and prognosis with a focus on genomics and related omics fields, development and application of novel technologies and methods, and translation to the clinic and population as well as back to the lab to inform biology.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Mayo Clinic, Rochester
United States
Zip Code
Block, Matthew S; Vierkant, Robert A; Rambau, Peter F et al. (2018) MyD88 and TLR4 Expression in Epithelial Ovarian Cancer. Mayo Clin Proc 93:307-320
Sharma, Ayush; Oishi, Naoki; Boddicker, Rebecca L et al. (2018) Recurrent STAT3-JAK2 fusions in indolent T-cell lymphoproliferative disorder of the gastrointestinal tract. Blood 131:2262-2266
Langlais, Blake T; Geyer, Holly; Scherber, Robyn et al. (2018) Quality of life and symptom burden among myeloproliferative neoplasm patients: do symptoms impact quality of life? Leuk Lymphoma :1-7
Yang, Ju Dong; Addissie, Benyam D; Mara, Kristin C et al. (2018) GALAD Score for Hepatocellular Carcinoma Detection in Comparison to Liver Ultrasound and Proposal of GALADUS Score. Cancer Epidemiol Biomarkers Prev :
Kurmi, Kiran; Hitosugi, Sadae; Yu, Jia et al. (2018) Tyrosine Phosphorylation of Mitochondrial Creatine Kinase 1 Enhances a Druggable Tumor Energy Shuttle Pathway. Cell Metab 28:833-847.e8
O'Mara, Tracy A; Glubb, Dylan M; Amant, Frederic et al. (2018) Identification of nine new susceptibility loci for endometrial cancer. Nat Commun 9:3166
Wallace, Sumer K; Halverson, Jessica W; Jankowski, Christopher J et al. (2018) Optimizing Blood Transfusion Practices Through Bundled Intervention Implementation in Patients With Gynecologic Cancer Undergoing Laparotomy. Obstet Gynecol 131:891-898
Shrestha, Shikshya; Zhang, Cheng; Jerde, Calvin R et al. (2018) Gene-Specific Variant Classifier (DPYD-Varifier) to Identify Deleterious Alleles of Dihydropyrimidine Dehydrogenase. Clin Pharmacol Ther 104:709-718
Hu, G; Dasari, S; Asmann, Y W et al. (2018) Targetable fusions of the FRK tyrosine kinase in ALK-negative anaplastic large cell lymphoma. Leukemia 32:565-569
Geller, James I; Fox, Elizabeth; Turpin, Brian K et al. (2018) A study of axitinib, a VEGF receptor tyrosine kinase inhibitor, in children and adolescents with recurrent or refractory solid tumors: A Children's Oncology Group phase 1 and pilot consortium trial (ADVL1315). Cancer 124:4548-4555

Showing the most recent 10 out of 1129 publications